Canaccord Genuity Morning Coffee on Columbia Labs (CBRX) and Watson Pharma (WPI): No Gel For You
Tweet Send to a FriendGet Alerts CBRX Hot Sheet
Price: $0.62 --0%
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 1 | New: 0
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 1 | New: 0
Trade CBRX Now!
Canaccord Genuity Morning Coffee on Columbia Labs (Nasdaq: CBRX) & Watson Pharmaceuticals (NYSE: WPI): No gel for you.
An advisory panel advised the FDA to reject a gel from Columbia Laboratories and Watson Pharmaceuticals, sending shares of the smaller Columbia tumbling on Monday. The gel, Prochieve, was aimed at reducing the risk of premature birth in women with a short cervix who are at higher risk of premature birth. A similar drug called Makena from K-V Pharmaceutical (NYSE: KV-A) is already available in the U.S., and the news sent shares of K-V higher on Monday.
Canaccord Genuity Life Sciences Analyst Randall Stanicky said the panel did not provide the upside surprise for Prochieve, which is disappointing, but he feels it is more than reflected in shares of Watson. He remains bullish on Watson, with his thesis intact despite the news regarding Prochieve. He believes today’s analyst meeting will provide a re-set bar that will leave several triggers to upside including an under-levered balance sheet and appetite for M&A.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
An advisory panel advised the FDA to reject a gel from Columbia Laboratories and Watson Pharmaceuticals, sending shares of the smaller Columbia tumbling on Monday. The gel, Prochieve, was aimed at reducing the risk of premature birth in women with a short cervix who are at higher risk of premature birth. A similar drug called Makena from K-V Pharmaceutical (NYSE: KV-A) is already available in the U.S., and the news sent shares of K-V higher on Monday.
Canaccord Genuity Life Sciences Analyst Randall Stanicky said the panel did not provide the upside surprise for Prochieve, which is disappointing, but he feels it is more than reflected in shares of Watson. He remains bullish on Watson, with his thesis intact despite the news regarding Prochieve. He believes today’s analyst meeting will provide a re-set bar that will leave several triggers to upside including an under-levered balance sheet and appetite for M&A.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Analyst Sees Potential for Omeros' (OMER) OMS824 as FDA Gives Clearance
- Topeka Capital Starts InvenSense (INVN) at Buy
- Hewlett-Packard (HPQ) Q2 Performance Wins Praise on Wall Street; Jefferies Raises to Hold
Create E-mail Alert Related Categories
Analyst Comments, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
